STOCK TITAN

Smith & Nephew plc - SNN STOCK NEWS

Welcome to our dedicated page for Smith & Nephew plc news (Ticker: SNN), a resource for investors and traders seeking the latest updates and insights on Smith & Nephew plc stock.

Smith & Nephew plc, also known as Smith+Nephew, is a leading British multinational medical equipment manufacturing company headquartered in Watford, England. Established in 1856, this pioneering firm excels in designing, manufacturing, and marketing advanced medical devices and technologies. Their core business areas include orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions.

Smith+Nephew's revenue is diversified across three main segments: Orthopedics (41%), Sports Medicine and ENT (30%), and Advanced Wound Therapy (29%). The United States contributes roughly half of the company’s total revenue, with other developed markets accounting for over 30%, and the remaining portion coming from emerging markets. The company operates in more than 100 countries and generated annual sales of $5.2 billion in 2022.

Recently, Smith+Nephew celebrated a significant milestone by receiving 510(k) clearance from the U.S. FDA for the AETOS Shoulder System. This advanced system is designed to enhance surgical experiences through greater intraoperative flexibility and fewer conversion steps and instruments, simplifying the operating room flow. The AETOS Shoulder System is part of the company's expanding Upper Extremity portfolio and complements its market-leading Sports Medicine shoulder repair and biologics solutions.

Another notable achievement includes the standout results of the REGENETEN Bioinductive Implant from a randomized controlled trial. This innovative implant substantially reduced re-tear rates in rotator cuff repairs, showcasing Smith+Nephew's commitment to improving patient outcomes through evidence-based solutions.

Smith+Nephew has also entered into a groundbreaking Master Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR). This agreement allows for collaborative research across all business units, fostering innovation and enhancing combat casualty care.

Moreover, the company launched the RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System in the US, which is a patient-centric option for treating chronic wounds. This system is designed for easy portability and quiet operation, making it suitable for patients' daily activities.

Smith+Nephew's purpose, 'Life Unlimited,' reflects their mission to help restore people's bodies and self-belief by using technology to enhance living. With 19,000 dedicated employees, the company continues to innovate and improve the quality of life for patients worldwide.

For more information about Smith+Nephew, please visit their official website and follow them on social media platforms such as Twitter, LinkedIn, Instagram, and Facebook.

Rhea-AI Summary

Smith+Nephew (NYSE:SNN) has received 510(k) clearance for its new CATALYSTEM Primary Hip System from the FDA. This system is designed to meet the evolving demands of primary hip surgery, including the increased adoption of anterior approach procedures and the expanding role of Ambulatory Surgery Centers (ASCs).

Key features of the CATALYSTEM system include:

  • A triple-taper stem design with uniform proximal loading
  • Reduced distal stem geometry and shorter lengths
  • Proprietary ACCUBROACH Technology for reproducibility between broach and implant
  • Compatibility with the CORI Surgical System

The system aims to provide precision fit, confidence in stem seating, and surgical efficiencies, making it suitable for diverse patient anatomies and various surgical approaches.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
none
-
Rhea-AI Summary

Smith+Nephew has launched the Orthopaedics for All initiative, creating a global advisory board to promote diversity, equity, and inclusion in orthopaedic surgery. The initiative aims to address the significant gender disparity in the field, where only 15% of orthopaedic residents and 7.4% of practicing surgeons in the U.S. are women. The board comprises around 20 leading female surgeons with a minimum of two years of post-fellowship experience. Smith+Nephew's initiative also includes partnerships, like with the Perry Initiative, to inspire young women to pursue careers in orthopaedics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
management
-
Rhea-AI Summary

Smith+Nephew (SNN), a global leader in medical technology, has announced its sponsorship of tennis players at Wimbledon 2024, aiming to spotlight its advanced Sports Medicine solutions. The company offers innovative solutions for common tennis injuries like rotator cuff and meniscus tears. Its REGENETEN Bioinductive Implant for rotator cuff repair has been used in over 100,000 procedures globally, showing significant clinical success. The FAST-FIX Family of meniscal repair solutions boasts a 30-year track record, aiding hundreds of thousands of patients with an 88% success rate in all-inside repairs. Smith+Nephew's sponsorship aligns with its mission to help individuals recover from injuries and return to their favorite activities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
Rhea-AI Summary

Smith+Nephew announced the launch of CORIOGRAPH Pre-Operative Planning and Modeling Services, enhancing its CORI Surgical System for knee arthroplasty procedures. This innovation aims to provide personalized solutions for surgeons and patients, integrating both image-based and image-free registration options. Dr. Steven Haas, an orthopaedic surgeon, recently completed the first procedures using these services, highlighting their potential to improve surgical efficiency and outcomes. The CORI Surgical System is built on over 15 years of expertise and includes tools like the CORI Digital Tensioner and updated RI.KNEE ROBOTICS 3.0 software.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
none
-
Rhea-AI Summary
Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s role in pressure injury prevention. The study by Professor Amit Gefen shows that ALLEVYN LIFE Dressing's layer-on-layer sliding phenomenon absorbs 30-45% of mechanical energy, potentially reducing pressure injury incidence. The unique frictional sliding mechanism enhances clinical efficacy, aligning with the need for shear mitigation in prevention dressings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
-
Rhea-AI Summary
Smith+Nephew's PICO Single Use Negative Pressure Wound Therapy System receives positive review from NICE for better clinical outcomes in high-risk patients at similar cost.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
none
Rhea-AI Summary
Smith+Nephew launches RENASYS EDGE NPWT System in the US to address chronic wounds, partnering with SunMED Medical Solutions and First Nation Group. The system aims to provide patient-centric care, reduce financial burden, and improve quality of life for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
none
-
Rhea-AI Summary
Smith+Nephew named Preferred Sports Medicine Technology Partner of UFC, promoting advanced technologies for repair and recovery. The partnership aims to benefit UFC athletes and fans by leveraging Smith+Nephew's cutting-edge Sports Medicine solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
none
-
Rhea-AI Summary
Smith+Nephew (LSE:SN, NYSE:SNN) partners with the U.S. Army Institute of Surgical Research in a groundbreaking Master CRADA. This collaboration aims to enhance combat casualty care through joint research efforts across various business units.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.47%
Tags
none
Rhea-AI Summary
Smith+Nephew (SNN) announces the full commercial availability of its AETOS Shoulder System in the US, with 510(k) clearance for use with ATLASPLAN 3D Planning Software. The system aims to enhance total shoulder arthroplasty procedures, offering stability, flexibility, and streamlined instrumentation. Developed in partnership with Materialise NV, it received FDA clearance in June 2023, expanding Smith+Nephew's Upper Extremity portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none

FAQ

What does Smith & Nephew specialize in?

Smith & Nephew specializes in orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions.

Where is Smith & Nephew headquartered?

Smith & Nephew is headquartered in Watford, England.

What are the main revenue segments of Smith & Nephew?

The main revenue segments are Orthopedics (41%), Sports Medicine and ENT (30%), and Advanced Wound Therapy (29%).

What recent achievement has Smith & Nephew made in orthopedic technology?

Smith & Nephew recently received 510(k) clearance from the U.S. FDA for the AETOS Shoulder System.

How does the REGENETEN Bioinductive Implant benefit patients?

The REGENETEN Bioinductive Implant significantly reduces re-tear rates in rotator cuff repairs, improving patient outcomes.

What is the purpose of Smith & Nephew's Master CRADA with the USAISR?

The Master CRADA aims to facilitate collaborative research across all business units, enhancing combat casualty care.

What is unique about the RENASYS EDGE NPWT System?

The RENASYS EDGE NPWT System is lightweight, portable, and operates quietly, making it ideal for patients' daily activities.

What is Smith & Nephew's company mission?

Smith & Nephew's mission is 'Life Unlimited,' focusing on restoring people's bodies and self-belief through advanced technology.

How many countries does Smith & Nephew operate in?

Smith & Nephew operates in more than 100 countries.

How can I learn more about Smith & Nephew?

For more information, visit their official website and follow them on social media platforms like Twitter, LinkedIn, Instagram, and Facebook.

Smith & Nephew plc

NYSE:SNN

SNN Rankings

SNN Stock Data

10.88B
874.35M
0.03%
8.11%
1.18%
Surgical Appliance and Supplies Manufacturing
Manufacturing
Link
United States of America
Watford